Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Case report

Cytarabine/venetoclax

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wang H, et al. Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis. British Journal of Haematology 201: 568-572, No. 3, May 2023. Available from: URL: https://onlinelibrary.wiley.com/doi/10.1111/bjh.18709 Wang H, et al. Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis. British Journal of Haematology 201: 568-572, No. 3, May 2023. Available from: URL: https://​onlinelibrary.​wiley.​com/​doi/​10.​1111/​bjh.​18709
Metadaten
Titel
Cytarabine/venetoclax
Lack of efficacy: case report
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-49509-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Multiple drugs